If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Tirzepatide: Use in Patients With Hepatitis
Tirzepatide has not been studied in people with hepatitis.
cFAQ
cFAQ
US_cFAQ_TZP036_HEPATITIS_NAFL
en-US
Detailed Information
There is no information on the use of tirzepatide in patients with hepatitis because patients were excluded from tirzepatide clinical trials if they had acute or chronic hepatitis, signs and symptoms of any liver disease other than NAFLD, or ALT ≤3.0 times the ULN. Patients with NAFLD were eligible to participate in this trial if their ALT was ≤3.0 times the ULN.
Glossary
ALT = alanine aminotransferase
NAFLD = nonalcoholic fatty liver disease
ULN = upper limit of normal
Date of Last Review: March 19, 2021
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon – Friday, 9am-7pm (EST), excluding holidays